↓ Skip to main content

Canadian hereditary angioedema guideline

Overview of attention for article published in Allergy, Asthma & Clinical Immunology, October 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (74th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

policy
1 policy source
twitter
4 X users

Citations

dimensions_citation
68 Dimensions

Readers on

mendeley
101 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Canadian hereditary angioedema guideline
Published in
Allergy, Asthma & Clinical Immunology, October 2014
DOI 10.1186/1710-1492-10-50
Pubmed ID
Authors

Stephen Betschel, Jacquie Badiou, Karen Binkley, Jacques Hébert, Amin Kanani, Paul Keith, Gina Lacuesta, Bill Yang, Emel Aygören-Pürsün, Jonathan Bernstein, Konrad Bork, Teresa Caballero, Marco Cicardi, Timothy Craig, Henriette Farkas, Hilary Longhurst, Bruce Zuraw, Henrik Boysen, Rozita Borici-Mazi, Tom Bowen, Karen Dallas, John Dean, Kelly Lang-Robertson, Benoît Laramée, Eric Leith, Sean Mace, Christine McCusker, Bill Moote, Man-Chiu Poon, Bruce Ritchie, Donald Stark, Gordon Sussman, Susan Waserman

Abstract

Hereditary angioedema (HAE) is a disease which is associated with random and often unpredictable attacks of painful swelling typically affecting the extremities, bowel mucosa, genitals, face and upper airway. Attacks are associated with significant functional impairment, decreased Health Related Quality of Life, and mortality in the case of laryngeal attacks. Caring for patients with HAE can be challenging due to the complexity of this disease. The care of patients with HAE in Canada is neither optimal nor uniform across the country. It lags behind other countries where there are more organized models for HAE management, and where additional therapeutic options are licensed and available for use. The objective of this guideline is to provide graded recommendations for the management of patients in Canada with HAE. This includes the treatment of attacks, short-term prophylaxis, long-term prophylaxis, and recommendations for self-administration, individualized therapy, quality of life, and comprehensive care. It is anticipated that by providing this guideline to caregivers, policy makers, patients and their advocates, that there will be an improved understanding of the current recommendations regarding management of HAE and the factors that need to be considered when choosing therapies and treatment plans for individual patients. The primary target users of this guideline are healthcare providers who are managing patients with HAE. Other healthcare providers who may use this guideline are emergency physicians, gastroenterologists, dentists and otolaryngologists, who will encounter patients with HAE and need to be aware of this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
Turkey 1 <1%
Germany 1 <1%
Brazil 1 <1%
Unknown 97 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 13%
Other 10 10%
Student > Master 9 9%
Student > Doctoral Student 8 8%
Student > Bachelor 8 8%
Other 22 22%
Unknown 31 31%
Readers by discipline Count As %
Medicine and Dentistry 43 43%
Pharmacology, Toxicology and Pharmaceutical Science 8 8%
Agricultural and Biological Sciences 4 4%
Nursing and Health Professions 3 3%
Social Sciences 3 3%
Other 8 8%
Unknown 32 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 January 2020.
All research outputs
#6,754,462
of 25,374,917 outputs
Outputs from Allergy, Asthma & Clinical Immunology
#359
of 924 outputs
Outputs of similar age
#68,933
of 274,199 outputs
Outputs of similar age from Allergy, Asthma & Clinical Immunology
#5
of 9 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 924 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.8. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 274,199 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.